A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients

Conditions: Hypertension Interventions: Drug: HGP2102-1; Drug: HGP2102-2; Drug: RLD2209-1; Drug: RLD2209-2 Sponsors: Hanmi Pharmaceutical Company Limited Not yet recruiting

Source: ClinicalTrials.gov - December 18, 2023 Category: Research Source Type: clinical trials